Agios Pharmaceuticals (AGIO) Research & Development (2012 - 2026)

Agios Pharmaceuticals has reported Research & Development for 15 years, with the latest figure at $81.1 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 11.55% year-over-year to $81.1 million; the trailing twelve-month figure through Mar 2026 stood at $347.9 million (up 13.93% YoY), and the FY2025 full-year result was $339.5 million, up 12.7% from the prior year.
• Research & Development for Q1 2026 stood at $81.1 million, down from $88.1 million in the prior quarter.
• The five-year high for Research & Development was $91.9 million in Q2 2025, with the low at $65.0 million in Q3 2022.
• Historically, Research & Development has averaged $76.3 million across 5 years, with a median of $74.5 million in 2022.
• Annual changes were most pronounced in 2023 — Research & Development grew 25.98% — and 2024, when it retreated 11.47%.
• Agios Pharmaceuticals' Research & Development stood at $70.3 million in 2022, then rose by 10.23% to $77.5 million in 2023, then grew by 6.87% to $82.8 million in 2024, then rose by 6.33% to $88.1 million in 2025, then decreased by 7.85% to $81.1 million in 2026.
• The last three Research & Development figures came in at $81.1 million (Q1 2026), $88.1 million (Q4 2025), and $86.8 million (Q3 2025), per Business Quant data.